Lifeward (LFWD) announced the expansion of patient access to the ReWalk Personal Exoskeleton through a new international distribution agreement with Verita Neuro, a Verita Healthcare Ltd. company. This collaboration supports Lifeward’s long-term growth strategy by extending its commercial footprint into new international markets through a partner-led, capital-efficient model. Verita Neuro has an established international footprint, with the partnership launching across multiple international geographies. Verita Neuro will be the exclusive distributor of ReWalk initially in Mexico, Thailand, and the United Arab Emirates, where it has advanced centers that offer innovative treatments for people living with neurological and spinal cord injuries.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFWD:
- Lifeward broadens coverage for ReWalk 7 Personal Robotic Exoskeleton
- Lifeward price target lowered to $4.50 from $13 at H.C. Wainwright
- Lifeward receives prior authorization from UnitedHealthcare for ReWalk 7
- Lifeward Ltd. Reports Q3 2025 Financial Results
- Lifeward Ltd. Earnings Call: Optimism Amid Challenges